Last reviewed · How we verify
Indobufen and aspirin mimetic
Indobufen is a platelet aggregation inhibitor that irreversibly acetylates cyclooxygenase, similar to aspirin, to prevent thrombotic events.
Indobufen is a platelet aggregation inhibitor that irreversibly acetylates cyclooxygenase, similar to aspirin, to prevent thrombotic events. Used for Prevention of thrombotic events in cardiovascular disease, Secondary prevention after myocardial infarction or stroke.
At a glance
| Generic name | Indobufen and aspirin mimetic |
|---|---|
| Sponsor | Beijing Anzhen Hospital |
| Drug class | Antiplatelet agent / Cyclooxygenase inhibitor |
| Target | Cyclooxygenase (COX) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Indobufen works by inhibiting platelet function through irreversible acetylation of cyclooxygenase enzymes, reducing thromboxane A2 synthesis and platelet aggregation. Like aspirin, it is used as an antiplatelet agent to prevent cardiovascular and cerebrovascular thrombotic events. The drug has been marketed primarily in Asia, particularly in China, for cardiovascular indications.
Approved indications
- Prevention of thrombotic events in cardiovascular disease
- Secondary prevention after myocardial infarction or stroke
Common side effects
- Gastrointestinal bleeding
- Dyspepsia
- Bruising/bleeding tendency
Key clinical trials
- INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE (PHASE4)
- GaStroEsophageal effeCt of indobUfen Versus aspiRin in Patients Undergoing Dual antiplatElet Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Indobufen and aspirin mimetic CI brief — competitive landscape report
- Indobufen and aspirin mimetic updates RSS · CI watch RSS
- Beijing Anzhen Hospital portfolio CI